Overview

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Status:
Unknown status

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to define an improvement in patients randomized in four different arms: Arm 1: R-MegaCHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 1BIS: R-CHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 2: R-MegaCHOP14x4 + R-MegaCHOP14x2; Arm 2BIS: R-CHOP14x4 + R-CHOP14x4; Which are different in dose dense chemotherapy + Rituximab with or without intensified high dose chemoimmunotherapy and support of peripheral autologous stem cells.

Phase:

Phase 3

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Collaborator:

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Treatments:

Cyclophosphamide
Cytarabine
Doxorubicin
Lenograstim
Liposomal doxorubicin
Mitoxantrone
Prednisone
Rituximab
Vincristine